Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?

Authors:
  • EWE. Waibler
    E. Waibler
  • PSP. Schulze
    P. Schulze
  • JSJ. Sehouli
    J. Sehouli
  • GOG. Oskay-Özcelik
    G. Oskay-Özcelik
  • TST. Schmook
    T. Schmook
  • WSW. Sterry
    W. Sterry
  • JLJ. Lademann
    J. Lademann
Open Access
Publisher website
Google Scholar
Abstract
Doxorubicin, one of the most potent single chemotherapeutic agents against solid and angiomatous tumors, is encapsulated in highly stable Stealth® liposomes so that its toxicity is significantly reduced [1]. The efficacy and toxicity of doxorubicin is affected by the different liposomal leakage rates; liposomes with the slowest rate of drug leakage showed the best therapeutic activity [2]. Nevertheless, severe and dose-limiting mucocutaneous reactions occur [3], mostly the palmar-plantar erythrodysesthesia syndrome (PPE). This syndrome is mainly located on the palms and plantae, but it may also affect intertrigeneous sites. A better understanding of the pathogenesis of PPE could provide the basis for its prevention and effective treatment.

This publication has 19 references indexed in Scilit: